Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14260951 | 1.00 | HSD11B1 (0.62) | HSD11B1HSD11B2 | |
| SCHEMBL4393907 | 0.90 | HSD11B1 (0.77) | HSD11B1HSD11B2 | |
| SCHEMBL14261076 | 0.90 | HSD11B1 (0.77) | HSD11B1HSD11B2 | |
| SCHEMBL1043091 | 0.90 | HSD11B1 (0.77) | HSD11B1HSD11B2 | |
| SCHEMBL14261093 | 0.89 | HSD11B1 (0.77) | HSD11B1HSD11B2 | |
| SCHEMBL4393817 | 0.88 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL14260995 | 0.88 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL14260981 | 0.87 | HSD11B1 (0.69) | HSD11B1HSD11B2 | |
| SCHEMBL4403544 | 0.87 | HSD11B1 (0.69) | HSD11B1HSD11B2 | |
| SCHEMBL1047213 | 0.86 | HSD11B1 (0.83) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344181-B2 | Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-01 | — | — | US | claimed |
| EP-1796657-B1 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | EP | claimed |
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-13 | — | — | US | claimed |
| US-8344181-B2 | Obesity, type 2 diabetes, hyperlipidemia, hypertension, arteriosclerosis, coronary heart diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-01-01 | — | — | US | disclosed |
| EP-1796657-B1 | N-2 ADAMANTANYL-2-PHENOXY-ACETAMIDE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-12-23 | — | — | EP | disclosed |
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064693-A1 | N-2 Adamantanyl-2-Phenoxy-Acetamide Derivatives as 11-Beta Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | HSD11B1 3/4885HSD11B2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.